New drug RPT1G enters human testing for tough blood cancers
Disease control
Recruiting now
This early-stage study is testing a new drug called RPT1G in 24 people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) whose cancer has returned or not responded to standard treatments. The main goals are to check if RPT1G is safe and to find the be…
Phase: PHASE1 • Sponsor: Remedy Plan, Inc. • Aim: Disease control
Last updated May 26, 2026 05:42 UTC